Organogenesis Holdings Inc - Asset Resilience Ratio
Organogenesis Holdings Inc (ORGO) has an Asset Resilience Ratio of 0.26% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2016)
This chart shows how Organogenesis Holdings Inc's Asset Resilience Ratio has changed over time. Check Organogenesis Holdings Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Organogenesis Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Organogenesis Holdings Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.16 Million | 0.26% |
| Total Liquid Assets | $1.16 Million | 0.26% |
Asset Resilience Insights
- Limited Liquidity: Organogenesis Holdings Inc maintains only 0.26% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Organogenesis Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Organogenesis Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401 |
Drug Manufacturers - Specialty & Generic | 5.09% |
|
KPC Pharmaceuticals Inc
SHG:600422 |
Drug Manufacturers - Specialty & Generic | 16.37% |
Annual Asset Resilience Ratio for Organogenesis Holdings Inc (2001–2016)
The table below shows the annual Asset Resilience Ratio data for Organogenesis Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 0.05% | $151.00K | $311.44 Million | -4.34pp |
| 2001-12-31 | 4.38% | $114.80K | $2.62 Million | -- |
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more